Collegium Pharmaceutical, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COLL research report →
Range $35 – $50
Price Chart
About the company
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions.
- CEO
- Vikram Karnani
- IPO
- 2015
- Employees
- 423
- HQ
- Stoughton, MA, US
Get TickerSpark's AI analysis on COLL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $768.18M
- P/E
- 20.94
- Fwd P/E
- 3.31
- PEG
- -0.61
- P/S
- 0.97
- P/B
- 2.73
- EV/EBITDA
- 4.55
- Div Yield
- 0.00%
- Gross Margin
- 59.05%
- Op Margin
- 14.81%
- Net Margin
- 4.68%
- ROE
- 12.49%
- ROIC
- 7.03%
Latest fiscal year · YoY change
- Revenue
- $780.57M+23.6%
- Gross Profit
- $463.26M+22.8%
- Op Income
- $187.08M
- Net Income
- $62.87M-9.1%
- EPS
- $1.98-7.5%
- OCF Growth
- +60.7%
- FCF Growth
- +61.1%
- 52W High
- $50.79
- 52W Low
- $21.43
- 50D MA
- $23.22
- 200D MA
- $31.72
- Beta
- 0.73
- RSI (14)
- 54
- Avg Volume
- 757.22K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Collegium reported record Q3 revenue, led by strong Jornay PM growth and an encouraging first full quarter for Azstarys, while reaffirming 2026 guidance despite pain-portfolio pressure.· November 5, 2026
- Record quarterly net product revenue of $216.3 million, up 3% year over year, with ADHD now above 36% of total revenue.
- Jornay PM remained the main growth engine: revenue rose to $59.5 million, up 24%, and prescriptions grew 16% year over year.
- Azstarys contributed $26.5 million in its first full quarter under Collegium ownership, with prescriptions up nearly 2% year over year.
- Pain products still generated substantial cash flow, but Xtampza and Nucynta declined year over year, reflecting payer pressure and generic competition.
- Management reaffirmed 2026 guidance and continued returning capital, including a $50 million accelerated share repurchase.
Total net product revenues were $216.3 million in Q3, up 3% year over year. Jornay PM net revenue was $51.9 million in the quarter, up 24% year over year. Azstarys net revenue was $26.5 million in its first full quarter under Collegium ownership. BELBUCA net revenue was $57.7 million, down 1% year over year; Xtampza ER was $45.8 million, down 9%; and total Nucynta franchise revenue was $30.8 million, down 44%, including $4.2 million from profit share on authorized generics. GAAP operating expenses were $96.7 million, up 44% year over year; adjusted operating expenses were $69.4 million, up 25%; GAAP net income was $21.8 million versus $31.5 million a year ago; non-GAAP adjusted EBITDA was $121.6 million, down 9%; GAAP EPS was $0.69 basic and $0.60 diluted versus $1.00 basic and $0.84 diluted; and adjusted EPS was $1.96 versus $2.25. Operating cash flow was $86.5 million, and cash, cash equivalents and marketable securities were $144.8 million at September 30, 2026. For 2026, management reaffirmed Jornay PM revenue guidance of $190 million to $200 million, Azstarys revenue guidance of $65 million to $75 million, total product revenue guidance of $825 million to $855 million, and adjusted EBITDA guidance of $445 million to $470 million.
Vikram Karnani said Collegium’s strategy remains centered on acquiring differentiated assets, integrating them quickly, and growing them, with ADHD now the lead growth driver. He emphasized that Jornay PM and Azstarys are complementary products that broaden the company’s reach across different ADHD patient types, and he highlighted continued investment in promotion, the sales force, and patient/caregiver awareness. His tone was constructive and confident, especially around the early progress with Azstarys and the long runway for both ADHD brands.
Colleen Tupper walked through the quarter’s financials, noting $216.3 million in total net product revenues, $121.6 million of adjusted EBITDA, and $86.5 million of operating cash flow. She highlighted cash and marketable securities of $144.8 million at quarter-end and said net debt to adjusted EBITDA was approximately 2x. On capital allocation, she reiterated the focus on business development, debt paydown, and opportunistic shareholder returns, including the $50 million accelerated share repurchase that began in Q3 and is expected to finish before year-end.
Analysts focused heavily on Azstarys, asking what could accelerate prescriptions and how gross-to-net could evolve; management said the first full quarter is early, but broader awareness, a larger 190-rep sales force, and new patient/caregiver marketing should support growth, while Q3 Azstarys gross-to-net was 73.4% versus 74.1% in Q2. Questions also centered on BELBUCA and the potential for a generic launch in 2027; management said they have not seen clear signs of a launch yet and are watching for FDA ANDA approval, compendia pricing, and wholesaler/distributor activity. On capital allocation and debt, management said the approach remains unchanged: use cash for BD, debt reduction, and buybacks as opportunities arise.
The quarter showed that Collegium can still grow the top line despite pressure in the legacy pain portfolio, with ADHD now contributing more than 36% of revenue and Jornay PM continuing to gain share. Management sounded optimistic that Azstarys is only at the beginning of its growth path, helped by a much larger commercial platform and expanding brand awareness.
The pain franchise is still under pressure, especially Nucynta and Xtampza, and management acknowledged payer pressure and generic competition as ongoing headwinds. Adjusted EBITDA and adjusted EPS were down year over year, and several questions on the call reflected uncertainty around Azstarys scaling, BELBUCA access changes, and the potential 2027 generic risk for BELBUCA.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.0%
- Shares Outstanding
- 31.08M
- Float Shares
- 28.29M
of shares held by institutions
284 13F filers
Buy/sell ratio 1.43. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.45M | ▲ 7.56K |
| Millennium Management LLC | 2.40M | ▲ 1.66M |
| Vanguard Group Inc | 2.26M | ▲ 29.88K |
| Jupiter Topco LLC | 2.15M | ▲ 2.15M |
| State Street Corp | 1.77M | ▲ 243.36K |
| Principal Financial Group Inc | 1.51M | ▼ 118.05K |
| Massachusetts Financial Services Co | 1.49M | ▲ 80.92K |
| Renaissance Technologies LLC | 1.41M | ▲ 41.85K |
| Vanguard Capital Management LLC | 1.38M | ▼ 6.03K |
| Eventide Asset Management, LLC | 1.36M | ▼ 917 |
| Woodline Partners LP | 1.31M | ▲ 1.23M |
| Invesco Ltd. | 1.26M | ▼ 621.46K |
Held by 321 ETFs
Biggest fund positions in COLL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Karnani Vikram | other | 11,737 |
| Jun 8, 26 | SANTINI GINO | other | 8,700 |
| Jun 8, 26 | SANTINI GINO | other | 8,700 |
| May 18, 26 | Freund John Gordon | sell | 20 |
| May 14, 26 | Lurker Nancy | other | 8,741 |
| May 14, 26 | Paya Carlos V | other | 8,741 |
| May 15, 26 | Freund John Gordon | other | 8,700 |
| May 15, 26 | Freund John Gordon | sell | 4,127 |
| May 14, 26 | Freund John Gordon | other | 8,741 |
| May 15, 26 | Freund John Gordon | other | 8,700 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our COLL coverage
Recent articles, reports, and earnings notes.
No research on COLL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COLL report →COLL or SDZNY: Which Is the Better Value Stock Right Now?
zacks.com · Nov 20
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
zacks.com · Nov 17
Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade
zacks.com · Nov 10
Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates
zacks.com · Nov 5
Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key Metrics
zacks.com · Nov 5
Collegium Pharmaceutical Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
globenewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.